Topotecan (Hycamtin®) in the Therapy of Small-Cell Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|21|4|13-17

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.21, Iss.4, 1999-01, pp. : 13-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hycamtin in the Therapy of Non-Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 18-21

Karger

Access to resources Recommend Favorite

Status of Topotecan in Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 1-1

Karger

Access to resources Recommend Favorite

Feasibility of Oral Topotecan in Previously Untreated Patients with Small-Cell Lung Cancer Ineligible for Standard Therapy

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 42-46

Karger

Access to resources Recommend Favorite

Topotecan in the First-Line Treatment of Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 13-17

Karger

Access to resources Recommend Favorite

Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where Is the Benefit?

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 7-8

Karger

Access to resources Recommend Favorite